Watson confirms Actavis acquisition in deal set to take group revenues to $8bn this year

With an upfront payment of €4.25 billion ($5.6 billion) and up to €250 million in future common stock to acquire the private Swiss firm Actavis Group, Watson Pharmaceuticals is now the third largest global generics company with anticipated 2012 pro forma revenues of $8 billion.